Skip to main content
SpringerLink
Log in

Genetics and imaging of pheochromocytomas and paragangliomas: current update

  • Special Section: Adrenal Gland
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare, heterogeneous neuroendocrine neoplasms of the autonomous nervous system of chromaffin cell origin that may arise within the adrenal medulla (PCCs) or the sympathetic and parasympathetic paraganglia (PGLs). Currently referred to by the umbrella term pheochromocytomas–paragangliomas (PPGLs), these distinct tumors are characterized by specific histopathology as well as biological and clinical profiles. PPGLs may occur as part of hereditary syndromes (40% of cases) or as sporadic tumors. Currently, there are 12 different hereditary syndromes with characteristic genetic abnormalities, at least 15 well-characterized driver genes and distinct tumor metabolic pathways. Based on the Cancer Genome Atlas (TCGA) taxonomic schemata, PPGLs have been classified into three main clusters of specific genetic mutations and tumor pathways with clinical, biochemical, and prognostic implications. Imaging plays a pivotal role in the initial diagnosis, tumor characterization, evaluation of treatment response, and long-term surveillance. While MDCT and MRI help in the anatomic localization, SPECT, and PET using different radiotracers are crucial in the functional assessment of these tumors. Surgery, chemotherapy, and radiotherapy are currently available treatment options for PPGLs; antiangiogenic drugs are also being used in treating metastatic disease. Evolving knowledge regarding the different genetic abnormalities involved in the pathogenesis of PPGLs has identified potential therapeutic targets that may be utilized in the discovery of novel drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21
Fig. 22

Similar content being viewed by others

References

  1. Opocher G, Schiavi F (2010) Genetics of pheochromocytomas and paragangliomas. Best practice & research Clinical endocrinology & metabolism 24 (6):943-956. https://doi.org/10.1016/j.beem.2010.05.001

    Article  CAS  Google Scholar 

  2. Fishbein L (2016) Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment. Hematol Oncol Clin North Am 30 (1):135-150. https://doi.org/10.1016/j.hoc.2015.09.006

    Article  PubMed  Google Scholar 

  3. Alrezk R, Suarez A, Tena I, Pacak K (2018) Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Front Endocrinol (Lausanne) 9:515. https://doi.org/10.3389/fendo.2018.00515

    Article  PubMed Central  Google Scholar 

  4. Lam AK (2017) Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. doi:https://doi.org/10.1007/s12022-017-9484-5

  5. DeLellis R (2004) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2004.

  6. Mercado-Asis LB, Wolf KI, Jochmanova I, Taieb D (2018) Pheochromocytoma: A Genetic and Diagnostic Update. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 24 (1):78-90. https://doi.org/10.4158/EP-2017-0057

    Article  Google Scholar 

  7. Lloyd RV (2017) WHO classification of tumours of endocrine organs. Lyon, France: IARC; 2017

  8. Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nature reviews Cancer 14 (2):108-119. https://doi.org/10.1038/nrc3648

    Article  CAS  PubMed  Google Scholar 

  9. Crona J, Taieb D, Pacak K (2017) New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev 38 (6):489-515. https://doi.org/10.1210/er.2017-00062

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nolting S, Grossman AB (2012) Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocrine pathology 23 (1):21-33. https://doi.org/10.1007/s12022-012-9199-6

    Article  CAS  PubMed  Google Scholar 

  11. Shah U, Giubellino A, Pacak K (2012) Pheochromocytoma: implications in tumorigenesis and the actual management. Minerva endocrinologica 37 (2):141-156

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Cancer Genome Atlas Research N, Pacak K, Nathanson KL, Wilkerson MD (2017) Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer cell 31 (2):181-193. https://doi.org/10.1016/j.ccell.2017.01.001

  13. Comino-Mendez I, de Cubas AA, Bernal C, Alvarez-Escola C, Sanchez-Malo C, Ramirez-Tortosa CL, Pedrinaci S, Rapizzi E, Ercolino T, Bernini G, Bacca A, Leton R, Pita G, Alonso MR, Leandro-Garcia LJ, Gomez-Grana A, Inglada-Perez L, Mancikova V, Rodriguez-Antona C, Mannelli M, Robledo M, Cascon A (2013) Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human molecular genetics 22 (11):2169-2176. https://doi.org/10.1093/hmg/ddt069

    Article  CAS  PubMed  Google Scholar 

  14. Galan SR, Kann PH (2013) Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clinical endocrinology 78 (2):165-175. https://doi.org/10.1111/cen.12071

    Article  CAS  PubMed  Google Scholar 

  15. Taieb D, Pacak K (2018) Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res 372 (2):393-401. https://doi.org/10.1007/s00441-018-2791-4

    Article  CAS  PubMed  Google Scholar 

  16. Frank-Raue K, Raue F (2009) Multiple endocrine neoplasia type 2 (MEN 2). Eur J Cancer 45 Suppl 1:267-273. https://doi.org/10.1016/S0959-8049(09)70041-3

    Article  PubMed  Google Scholar 

  17. Wohllk N, Schweizer H, Erlic Z, Schmid KW, Walz MK, Raue F, Neumann HP (2010) Multiple endocrine neoplasia type 2. Best practice & research Clinical endocrinology & metabolism 24 (3):371-387. https://doi.org/10.1016/j.beem.2010.02.001

    Article  CAS  Google Scholar 

  18. Wells SA, Jr., Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25 (6):567-610. https://doi.org/10.1089/thy.2014.0335

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, Giustini S, Sciomer S, Anastasi E, Calvieri S, De Toma G, Letizia C (2011) Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 303 (5):317-325. https://doi.org/10.1007/s00403-010-1090-z

    Article  PubMed  Google Scholar 

  20. Zografos GN, Vasiliadis GK, Zagouri F, Aggeli C, Korkolis D, Vogiaki S, Pagoni MK, Kaltsas G, Piaditis G (2010) Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World journal of surgical oncology 8:14. https://doi.org/10.1186/1477-7819-8-14

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jafri M, Maher ER (2012) The genetics of phaeochromocytoma: using clinical features to guide genetic testing. European journal of endocrinology / European Federation of Endocrine Societies 166 (2):151-158. https://doi.org/10.1530/eje-11-0497

    Article  CAS  Google Scholar 

  22. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatrics 123 (1):124-133. https://doi.org/10.1542/peds.2007-3204

    Article  PubMed  Google Scholar 

  23. Maher ER, Neumann HP, Richard S (2011) von Hippel-Lindau disease: a clinical and scientific review. European journal of human genetics : EJHG 19(6):617-623. https://doi.org/10.1038/ejhg.2010.175

    Article  CAS  PubMed  Google Scholar 

  24. Karasek D, Frysak Z, Pacak K (2010) Genetic testing for pheochromocytoma. Current hypertension reports 12(6):456-464. https://doi.org/10.1007/s11906-010-0151-1

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kantorovich V, King KS, Pacak K (2010) SDH-related pheochromocytoma and paraganglioma. Best practice & research Clinical endocrinology & metabolism 24 (3):415-424. https://doi.org/10.1016/j.beem.2010.04.001

    Article  CAS  Google Scholar 

  26. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, European-American Paraganglioma Study Group (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (8):943-951. https://doi.org/10.1001/jama.292.8.943

  27. Barber B, Ingram M, Khan S, Bano G, Hodgson S, Vlahos I (2011) Clinicoradiological manifestations of paraganglioma syndromes associated with succinyl dehydrogenase enzyme mutation. Insights into imaging 2 (4):431-438. https://doi.org/10.1007/s13244-011-0096-1

    Article  PubMed  PubMed Central  Google Scholar 

  28. Evenepoel L, Papathomas TG, Krol N, Korpershoek E, de Krijger RR, Persu A, Dinjens WN (2015) Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med 17 (8):610-620. https://doi.org/10.1038/gim.2014.162

    Article  CAS  PubMed  Google Scholar 

  29. Alrashdi I, Bano G, Maher ER, Hodgson SV (2010) Carney triad versus Carney Stratakis syndrome: two cases which illustrate the difficulty in distinguishing between these conditions in individual patients. Familial cancer 9 (3):443-447. https://doi.org/10.1007/s10689-010-9323-z

    Article  PubMed  Google Scholar 

  30. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie G, Baudin E, Chompret A, Ellison JW, Briere JJ, Rustin P, Gimenez-Roqueplo AP, Eng C, Carney JA, Stratakis CA (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European journal of human genetics : EJHG 16 (1):79-88. https://doi.org/10.1038/sj.ejhg.5201904

    Article  CAS  PubMed  Google Scholar 

  31. Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Bertz H, Walz MK, Moeller LC, Schmid KW, Eng C (2011) Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. The Journal of clinical endocrinology and metabolism 96(8):E1279-1282. https://doi.org/10.1210/jc.2011-0114

    Article  CAS  PubMed  Google Scholar 

  32. Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, Inglada-Perez L, de Cubas AA, Amar L, Barontini M, de Quiros SB, Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD, Corssmit EP, Giacche M, de Krijger RR, Ercolino T, Girerd X, Gomez-Garcia EB, Gomez-Grana A, Guilhem I, Hes FJ, Honrado E, Korpershoek E, Lenders JW, Leton R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18(10):2828-2837. https://doi.org/10.1158/1078-0432.CCR-12-0160

    Article  CAS  PubMed  Google Scholar 

  33. Favier J, Amar L, Gimenez-Roqueplo AP (2015) Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11(2):101-111. https://doi.org/10.1038/nrendo.2014.188

    Article  CAS  PubMed  Google Scholar 

  34. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, Hahn PF, Boland GW (2004) Pheochromocytoma: an imaging chameleon. Radiographics 24(Suppl 1):S87-99. https://doi.org/10.1148/rg.24si045506

    Article  PubMed  Google Scholar 

  35. Leung K, Stamm M, Raja A, Low G (2013) Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol 200(2):370-378. https://doi.org/10.2214/AJR.12.9126

    Article  PubMed  Google Scholar 

  36. Patel J, Davenport MS, Cohan RH, Caoili EM (2013) Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol 201(1):122-127. https://doi.org/10.2214/AJR.12.9620

    Article  PubMed  Google Scholar 

  37. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD (2016) Comparison of Quantitative MRI and CT Washout Analysis for Differentiation of Adrenal Pheochromocytoma From Adrenal Adenoma (2016) Comparison of Quantitative MRI and CT Washout Analysis for Differentiation of Adrenal Pheochromocytoma From Adrenal Adenoma. AJR Am J Roentgenol 206 (6):1141-1148. https://doi.org/10.2214/AJR.15.15318

    Article  PubMed  Google Scholar 

  38. Bessell-Browne R, O’Malley ME (2007) CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol 188 (4):970-974. https://doi.org/10.2214/ajr.06.0827

  39. Low G, Dhliwayo H, Lomas DJ (2012) Adrenal neoplasms. Clinical radiology 67 (10):988-1000. https://doi.org/10.1016/j.crad.2012.02.005

    Article  CAS  PubMed  Google Scholar 

  40. Blake MA, Cronin CG, Boland GW (2010) Adrenal imaging. AJR American journal of roentgenology 194 (6):1450-1460. https://doi.org/10.2214/AJR.10.4547

    Article  PubMed  Google Scholar 

  41. Lee TH, Slywotzky CM, Lavelle MT, Garcia RA (2002) Cystic pheochromocytoma. Radiographics : a review publication of the Radiological Society of North America, Inc 22 (4):935-940

  42. Munden R, Adams DB, Curry NS (1993) Cystic pheochromocytoma: radiologic diagnosis. Southern medical journal 86 (11):1302-1305

    Article  CAS  Google Scholar 

  43. Hanna JS, Spencer PJ, Savopoulou C, Kwasnik E, Askari R (2011) Spontaneous adrenal pheochromocytoma rupture complicated by intraperitoneal hemorrhage and shock. World journal of emergency surgery : WJES 6 (1):27. https://doi.org/10.1186/1749-7922-6-27

    Article  PubMed  Google Scholar 

  44. Dong Y, Liu Q (2012) Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput Assist Tomogr 36 (4):361-366. https://doi.org/10.1097/rct.0b013e31825975f8

  45. Lee KY, Oh YW, Noh HJ, Lee YJ, Yong HS, Kang EY, Kim KA, Lee NJ (2006) Extraadrenal paragangliomas of the body: imaging features. AJR Am J Roentgenol 187 (2):492-504. https://doi.org/10.2214/AJR.05.0370

    Article  PubMed  Google Scholar 

  46. van den Berg R (2005) Imaging and management of head and neck paragangliomas. European radiology 15 (7):1310-1318. https://doi.org/10.1007/s00330-005-2743-8

    Article  PubMed  Google Scholar 

  47. Otake Y, Aoki M, Imamura N, Ishikawa M, Hashimoto K, Fujiyama R (2006) Aortico-pulmonary paraganglioma: case report and Japanese review. The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 54 (5):212-216. https://doi.org/10.1007/bf02670315

  48. da Silva RA, Gross JL, Haddad FJ, Toledo CA, Younes RN (2006) Primary pulmonary paraganglioma: case report and literature review. Clinics 61 (1):83-86. https://doi.org/10.1590/S1807-59322006000100015

    Article  PubMed  Google Scholar 

  49. Aubertine CL, Flieder DB (2004) Primary paraganglioma of the lung. Annals of diagnostic pathology 8 (4):237-241

    Article  Google Scholar 

  50. Woolen S, Gemmete JJ (2016) Paragangliomas of the Head and Neck. Neuroimaging Clin N Am 26 (2):259-278. https://doi.org/10.1016/j.nic.2015.12.005

    Article  PubMed  Google Scholar 

  51. Angelousi A, Kassi E, Zografos G, Kaltsas G (2015) Metastatic pheochromocytoma and paraganglioma. Eur J Clin Invest 45 (9):986-997. https://doi.org/10.1111/eci.12495

    Article  CAS  PubMed  Google Scholar 

  52. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF, Jr., Endocrine Society (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism 99 (6):1915-1942. https://doi.org/10.1210/jc.2014-1498

    Article  CAS  PubMed  Google Scholar 

  53. Raja A, Leung K, Stamm M, Girgis S, Low G (2013) Multimodality imaging findings of pheochromocytoma with associated clinical and biochemical features in 53 patients with histologically confirmed tumors. AJR Am J Roentgenol 201 (4):825-833. https://doi.org/10.2214/AJR.12.9576

    Article  PubMed  Google Scholar 

  54. Janssen I, Wolf KI, Chui CH, Millo CM, Pacak K (2017) Relevant Discordance Between 68 Ga-DOTATATE and 68 Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key? Clin Nucl Med 42 (3):211-213. https://doi.org/10.1097/RLU.0000000000001504

    Article  PubMed  PubMed Central  Google Scholar 

  55. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104 (9):700-708. https://doi.org/10.1093/jnci/djs188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hentschel M, Rottenburger C, Boedeker CC, Neumann HP, Brink I (2012) Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? Clinical nuclear medicine 37 (2):e24-29. https://doi.org/10.1097/RLU.0b013e318238f550

    Article  PubMed  Google Scholar 

  57. Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D (2015) 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocrine-related cancer 22 (4):T135-145. https://doi.org/10.1530/ERC-15-0175

    Article  CAS  PubMed  Google Scholar 

  58. Roman-Gonzalez A, Jimenez C (2017) Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. Curr Opin Endocrinol Diabetes Obes 24 (3):174-183. https://doi.org/10.1097/MED.0000000000000330

    Article  PubMed  Google Scholar 

  59. Eisenhofer G, Tischler AS, de Krijger RR (2012) Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocrine pathology 23 (1):4-14. https://doi.org/10.1007/s12022-011-9188-1

    Article  CAS  PubMed  Google Scholar 

  60. Dhir M, Li W, Hogg ME, Bartlett DL, Carty SE, McCoy KL, Challinor SM, Yip L (2017) Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Ann Surg Oncol 24 (12):3624-3630. https://doi.org/10.1245/s10434-017-6074-1

    Article  PubMed  Google Scholar 

  61. Suh YJ, Choe JY, Park HJ (2017) Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA. Endocrine pathology 28 (2):159-164. https://doi.org/10.1007/s12022-017-9479-2

    Article  PubMed  Google Scholar 

  62. Costa MH, Ortiga-Carvalho TM, Violante AD, Vaisman M (2015) Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol (Lausanne) 6:126. https://doi.org/10.3389/fendo.2015.00126

    Article  Google Scholar 

  63. Iacobone M, Schiavi F, Bottussi M, Taschin E, Bobisse S, Fassina A, Opocher G, Favia G (2011) Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas? Surgery 150 (6):1194-1201. https://doi.org/10.1016/j.surg.2011.09.024

    Article  PubMed  Google Scholar 

  64. King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K (2011) Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29 (31):4137-4142. https://doi.org/10.1200/JCO.2011.34.6353

    Article  CAS  Google Scholar 

  65. Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM (2014) The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology 83 (6):1225-1232. https://doi.org/10.1016/j.urology.2014.01.007

    Article  PubMed  PubMed Central  Google Scholar 

  66. Waingankar N, Bratslavsky G, Jimenez C, Russo P, Kutikov A (2016) Pheochromocytoma in Urologic Practice. Eur Urol Focus 1 (3):231-240. https://doi.org/10.1016/j.euf.2015.09.011

    Article  PubMed  PubMed Central  Google Scholar 

  67. Grogan RH, Mitmaker EJ, Duh QY (2011) Changing paradigms in the treatment of malignant pheochromocytoma. Cancer control : journal of the Moffitt Cancer Center 18 (2):104-112

    Article  Google Scholar 

  68. Angelousi A, Dimitriadis GK, Zografos G, Nolting S, Kaltsas G, Grossman A (2017) Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. Endocr Relat Cancer 24 (6):R239-R259. https://doi.org/10.1530/ERC-16-0542

    Article  PubMed  Google Scholar 

  69. Mohammed AA, El-Shentenawy AM, Sherisher MA, El-Khatib HM (2014) Target therapy in metastatic pheochromocytoma: current perspectives and controversies. Oncol Rev 8(2):249. https://doi.org/10.4081/oncol.2014.249

    Article  PubMed  PubMed Central  Google Scholar 

  70. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97(11):4040-4050. https://doi.org/10.1210/jc.2012-2356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA

    Venkata S. Katabathina, Hamid Rajebi, Carlos S. Restrepo & Umber Salman

  2. University of Texas MD Anderson Cancer Center, Houston, USA

    Melissa Chen, Raghu Vikram & Srinivasa R. Prasad

  3. Mayo Clinic at Scottsdale, Scottsdale, USA

    Christine O. Menias

Authors
  1. Venkata S. Katabathina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Rajebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melissa Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos S. Restrepo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Umber Salman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raghu Vikram
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine O. Menias
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Srinivasa R. Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Venkata S. Katabathina.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katabathina, V.S., Rajebi, H., Chen, M. et al. Genetics and imaging of pheochromocytomas and paragangliomas: current update. Abdom Radiol 45, 928–944 (2020). https://doi.org/10.1007/s00261-019-02044-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-019-02044-w

Keywords

Search

Navigation